AKTS Aktis Oncology, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2035832 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets13.8%
Debt / equity0.00x
Current ratio14.22x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $3.90M | $3.38M | $3.23M | $1.58M | $1.60M | $1.45M |
| R&D expense | $32.12M | $25.28M | $20.04M | $16.47M | $18.63M | $15.86M |
| SG&A expense | $6.53M | $7.00M | $5.90M | $3.31M | $3.94M | $3.73M |
| Operating income | -$34.75M | -$28.90M | -$22.71M | -$18.20M | -$20.96M | -$18.14M |
| Net income | -$29.94M | -$24.14M | -$18.32M | -$15.53M | -$18.07M | -$14.98M |
| EBITDA | -$33.75M | -$28.00M | -$22.05M | -$17.60M | -$20.36M | -$17.66M |
| EPS (basic) | -0.54 | -0.44 | -0.38 | -19.18 | -22.39 | -18.60 |
| EPS (diluted) | -0.54 | -0.44 | -0.38 | -19.18 | -22.39 | -18.60 |
| Weighted avg. shares (diluted) | 55.65M | 55.30M | 48.63M | 809,765 | 807,281 | 805,821 |
| Balance sheet | ||||||
| Cash & equivalents | $68.32M | $82.49M | $371.63M | $180.25M | $110.22M | $58.25M |
| Current assets | $499.89M | $524.54M | $543.94M | — | — | — |
| PP&E, net | $15.37M | $15.97M | $15.29M | — | — | — |
| Total assets | $532.48M | $557.60M | $576.80M | — | — | — |
| Current liabilities | $35.16M | $32.13M | $27.91M | — | — | — |
| Total liabilities | $73.61M | $72.76M | $70.69M | — | — | — |
| Shareholders' equity | $458.87M | $484.84M | $506.11M | -$132.39M | -$118.20M | -$101.56M |
| Shares outstanding | 53.91M | 53.45M | 53.40M | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$26.05M | -$20.59M | -$24.24M | -$15.22M | -$16.18M | -$17.48M |
| Capital expenditure | $772,000 | $1.26M | $1.85M | $2.00M | $1.53M | $1.89M |
| Free cash flow | -$26.82M | -$21.85M | -$26.10M | -$17.23M | -$17.71M | -$19.38M |
| Investing cash flow | $10.17M | -$268.71M | $20.54M | $85.23M | $68.14M | $39.04M |
| Financing cash flow | $1.71M | $156,000 | $337.55M | $28,000 | $0 | -$468,000 |
| Depreciation & amortization | $1.00M | $900,000 | $652,000 | $600,000 | $600,000 | $484,000 |
| Stock-based compensation | $3.45M | $3.22M | $3.02M | $1.28M | $1.52M | $1.24M |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.